By Dr. Ahmad Sheikh, AbbVie While new chemical entities represent majority of the drugs approved in the last five years, the diversity and complexity of these molecules continue...
By Dr. Jeremy M. Merritt, Eli Lilly and Co. Abstract: pending
Dr. Jeremy M. Merritt is a Director at Eli Lilly and Co. in the small molecule design and development organization (SMDD). He currently leads the Particle Design Lab (PDL)...
Moderator: Dr. Alfred Lee, Merck
Moderator: Dr. Kevin Girard, Pfizer
Moderator: Dr. Christopher Burcham, Eli Lilly and Company
Particle surface engineering is a cost-effective, promising route to achieve enhancements in the flowability, bulk density and other properties of a variety of cohesive active pharmaceutical ingredients (APIs). This...
In solution phase crystallisation processes, understanding and controlling the transition pathway associated with the assembly of molecules from their solvated state, into three-dimensional, ordered crystalline-solids, represents a significant grand...
Dr. Alfred Lee, Merck Research Laboratories
